Nyxoah Celebrates Milestone with U.S. Genio System Launch
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a trailblazer in medical technology, announces a groundbreaking achievement with its Genio system aimed at treating Obstructive Sleep Apnea (OSA). Recently, the first patients in the U.S. received their Genio implants, marking a significant step in enhancing patient care across the nation.
A New Era in Sleep Apnea Treatment
The excitement surrounding the Genio system reflects its potential effectiveness and the strong demand for innovative solutions to combat OSA. Olivier Taelman, CEO of Nyxoah, expressed his enthusiasm, stating, "We are thrilled to announce that the first commercial patients have now received Genio implants, marking a significant milestone in bringing this innovative therapy to OSA patients in the U.S." This enthusiasm is echoed by heightened interest from surgeons eager to be trained and ready for this new procedure.
Expert Insights on the Genio System
Dr. Andrew T. Huang, a noted surgeon specializing in sleep surgery, was among the first to implant the Genio devices. Performing five procedures in a week, he noted the effectiveness of the device in providing symmetrical tongue protrusion. Dr. Huang emphasized that this innovation addresses the needs of patients who prefer fewer incisions and beneficial bilateral stimulation for their airway anatomy.
Transforming Sleep Apnea Management
As OSA presents significant health challenges, it is crucial to expand access to cutting-edge treatments like the Genio system. The positive reception from healthcare providers indicates a growing commitment to overcoming the hurdles associated with sleep apnea management.
Metrics Indicating Future Growth
Nyxoah is focused on several key performance indicators to gauge future growth within the U.S. market, including:
- Number of trained surgeons pursuing the procedure
- Submissions for value analysis committee reviews
- Prior authorization requests
- New account registrations for the Genio system
These metrics are critical in forecasting the adoption and success of the Genio system.
About Nyxoah and Its Vision
Nyxoah is committed to developing transformative solutions for patients suffering from OSA. The Genio system is designed as a patient-centric, leadless, and battery-free hypoglossal neurostimulation therapy. With OSA being the most prevalent form of sleep-disordered breathing linked with serious health risks, Nyxoah’s vision is to ensure that patients enjoy restful nights and can live life fully.
Recent Developments and Approvals
After successfully conducting the BLAST OSA study, Nyxoah obtained the European CE Mark for the Genio system in 2019. The company has celebrated two successful IPOs and continues to gain recognition for positive outcomes from various studies, including the DREAM IDE pivotal study, leading up to its FDA approval.
Contact Nyxoah for More Information
For further details about Nyxoah and the Genio system, feel free to reach out to: John Landry, CFO at IR@nyxoah.com.
Frequently Asked Questions
What is the Genio system?
The Genio system is an innovative, leadless, and battery-free therapy designed to treat Obstructive Sleep Apnea by stimulating the hypoglossal nerve.
Who can benefit from the Genio therapy?
Patients suffering from OSA who prefer a less invasive solution with fewer complications can benefit from the Genio therapy.
Where has the Genio system been launched?
Recently, the Genio system was launched in the U.S., marking its availability for commercial implantation.
What are the expected outcomes of the Genio therapy?
By providing tongue stimulation, the Genio therapy aims to reduce the severity of OSA symptoms, improving sleep quality and overall health.
How can interested patients learn more about the Genio system?
Patients can inquire about the Genio system through their healthcare provider or contact Nyxoah directly for more information.
